Dr. Reddys Laboratories is currently trading at Rs. 2736.25, up by 11.15 points or 0.41% from its previous closing of Rs. 2725.10 on the BSE.
The scrip opened at Rs. 2727.50 and has touched a high and low of Rs. 2761.50 and Rs. 2726.30 respectively. So far 7732 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2965.20 on 02-May-2019 and a 52 week low of Rs. 2065.30 on 15-Feb-2019.
Last one week high and low of the scrip stood at Rs. 2791.00 and Rs. 2693.35 respectively. The current market cap of the company is Rs. 45474.09 crore.
The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 44.50% and 14.44% respectively.
Dr. Reddy's Laboratories has launched Lansoprazole Delayed-Release Capsules USP, 15 mg, an over-the-counter (OTC) store-brand equivalent of Prevacid 24HR Capsules, in the United States market, as approved by the US Food and Drug Administration (USFDA).
Dr. Reddy's OTC Lansoprazole Delayed-Release Capsules USP, 15 mg, is an over-the-counter, Proton Pump Inhibitor (PPI) used to treat frequent heartburn occurring two or more days a week.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1501.40 |
Dr. Reddys Lab | 6267.20 |
Cipla | 1406.35 |
Zydus Lifesciences | 947.45 |
Lupin | 1613.00 |
View more.. |